News
The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.
The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.
Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback